Phase II Study of the Modified Regimen of Etoposide, Leucovorin and 5-Fluorouracil for Patients with Advanced Gastric Cancer

Tzeon Jye Chiou, Shiao Lin Tung, Ruey Kuen Hsieh, Wei Shu Wang, Chueh Chuan Yen, Frank S. Fan, Jin Hwang Liu, Po Min Chen

研究成果: 雜誌貢獻文章同行評審

8 引文 斯高帕斯(Scopus)

摘要

Background: The efficacy of the treatment of advanced gastric cancer is not very good. The response rate to the original etoposide-leucovorin-5-fluorouracil (ELF) treatment is 53% with tolerable side effects. Whether increasing the dose intensity by prolonging the duration of infusion with 5-fluorouracil (5-FU) and leucovorin (LV) from 3 to 5 days for advanced or metastatic gastric cancer patients would enhance the efficacy but not increase side effects is still unknown. Methods: Thirty-six advanced or metastatic gastric cancer and chemotherapy-naïve patients with measurable or evaluable diseases were scheduled to receive intravenous etoposide 100 mg/m2/day on days 2-4, LV 300 mg/m2/day intravenously and 5-FU 500 mg/m2/day intravenously on days 1-5, every 4 weeks. All patients who received at least two courses of chemotherapy were evaluated for tumor response, survival and response duration and toxicity according to the WHO criteria. Results: Thirteen patients showed a response, including five with complete response (CR). The overall response rate was 36% (95% confidence interval, CI, 20-52%) in the whole group and 46% (95% CI 28-66%) in the 28 patients with measurable disease. The median progression-free interval and overall median survival time were 5 and 7 months, respectively. The most frequent toxicity was alopecia (grade I/II 56.3%). The incidence of grade III or greater myelosuppression was 5.9%. No treatment-related death occurred. Conclusions: The efficacy of the modified ELF by increasing the dosages of 5-FU and LV is not superior to the results of the original regimen, yet it is a relatively safe and tolerable combination regimen for advanced gastric cancer.
原文英語
頁(從 - 到)318-322
頁數5
期刊Japanese Journal of Clinical Oncology
28
發行號5
DOIs
出版狀態已發佈 - 1998
對外發佈

ASJC Scopus subject areas

  • 腫瘤科
  • 放射學、核子醫學和影像學
  • 癌症研究

指紋

深入研究「Phase II Study of the Modified Regimen of Etoposide, Leucovorin and 5-Fluorouracil for Patients with Advanced Gastric Cancer」主題。共同形成了獨特的指紋。

引用此